Biotech entity
All 1 tracked stories fall under one category: pharma. Bachem is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Lonza, all published on March 11, 2026. Each carries 2 original sources on average.
Last mentioned: Mar 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Bachem is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Lonza, all published on March 11, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lonza. Shared-story counts are live from our verified record — not editorial picks.
Bachem (BCHMF) is set to release its quarterly earnings this Thursday, with investors closely monitoring the Swiss CDMO's ability to scale production for the booming GLP-1 market. As a critical supplier of peptides and oligonucleotides, Bachem's financial performance and capacity expansion updates will serve as a bellwether for the broader weight-loss drug supply chain.
Source: themarketsdaily.com · tickerreport.com
Lonza is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
